IL1RL2 and generalized pustular psoriasis: To date, intravenous spesolimab, an anti-IL-36R monoclonal antibody, is the only Health Canada-approved treatment of flares in adult generalized pustular psoriasis patients, while subcutaneous spesolimab is the only Health Canada-approved maintenance treatment for long-term management of adult generalized pustular psoriasis patients to minimize relapse.